Predicting dementia in the first 6 years of Parkinson’s disease in the ICICLE-PD cohort
Objective: To determine which baseline cognitive tests in newly diagnosed participants with Parkinson’s disease (PD) predict conversion to dementia (PDD) within six years. Background: Cognitive…Decreased Regional Cholinergic Signaling in Parkinson’s Disease
Objective: To identify regions of decreased cholinergic signaling in Parkinson's disease (PD) participants relative to cognitively normal controls as measured by positron emission tomography imaging…Serum microRNA-29 family as potential biomarkers for cognitive impairment in Parkinson’s disease
Objective: To examine whether miRNA-29s (miR-29s) in serum could be used as biomarkers for either Parkinson’s disease with dementia (PDD) or Parkinson’s disease with mild…Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patients and controls: the PPMI study
Objective: To test the correlations between longitudinal measurements of glucocerebrosidase (GCase; encoded by GBA) enzymatic activity and Parkinson’s disease (PD) phenotype in the Parkinson’s Progression…A Fluctuating Qualitative Dermatoglyphic Trait, Dankmeijer’s and Furuhata’s Index as a Risk Marker in Diabetic Parkinson’s Patients of Guyana: A Case-Control Study
Objective: The current study aims to compare and evaluate the fluctuating qualitative dermatoglyphic trait, Furuhata’s and Dankmeijer’s index as a risk marker in Diabetes and…Early predictors of Parkinson’s disease and prognosis in relatives
Objective: To study early clinical and biochemical markers of Parkinson's disease (PD) in relatives of Uzbek nationality. Background: Parkinson's disease is a neurodegenerative hereditary disease…DJ1 and α-Synuclein as CSF biomarkers and gene polymorphisms: association with clinical parameters in Parkinson’s disease
Objective: To analyze the CSF α-Synuclein and DJ1 Biomarkers correlating with SNCA and DJ1 gene polymorphisms and clinical parameters in PD. Background: Currently there is…Multiplex biomarker discovery for diagnostic and progression markers for Parkinson’s disease with the proximity extension assay technology on inflammation-related analytes
Objective: To identify diagnostic and progression biomarkers in the longitudinal DeNoPa cohort of (at enrolment) de novo Parkinson’s disease (PD) and healthy controls (HC) using…L-DOPA treatment in N2a cells stimulates neuromelanin biosynthesis: Using a novel in vitro model to examine the effect of iron and light on neuromelanin production
Objective: Naturally-occuring quantities of in vivo neuromelanin (NM) are low, and the collection of NM from tissue involves laborious extraction and isolation. Thus, in vitro…The feasibility of detailed phenotyping of muscle mitochondrial respiratory chain function and content in Parkinson’s disease
Objective: We aimed to determine: 1) the feasibility of obtaining and characterising skeletal muscle; and 2) if muscle mitochondrial respiratory chain (MRC) function and content…
- « Previous Page
- 1
- …
- 73
- 74
- 75
- 76
- 77
- …
- 149
- Next Page »